Uniqure
QURE----
Uniqure (QURE)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows p...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Uniqure Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$64.8766.45%
Forecast & RatingStrong buy
13analysts
- Strong buy69.23%
- Buy15.38%
- Hold15.38%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan · Jul 21 at 10:05 PM
uniQure to Announce Second Quarter 2026 Financial Results | QURE Stock News
- Global Report · Jul 15 at 04:14 AM
Global Markets at a Crossroads: From Macro Hedges to Supply Chain Rewiring
- InvestorPlace · Jul 8 at 09:15 AM
3 Biotech Stocks to Watch Before Wall Street Catches On
- PUBT · Jul 7 at 03:48 PM
uniQure CEO Matthew Kapusta disposes of USD 956,528 in common shares
- Market Beat · Jul 2 at 04:07 PM
Walid Abi-Saab Sells 30,000 Shares of uniQure (NASDAQ:QURE) Stock
- PUBT · Jul 2 at 03:56 PM
uniQure director Jack Kaye disposes of ordinary shares worth $954,615.3
